Patents expiring in 2040

US 10633363

EPAC1 activators as HIV latency reversal agents (LRA)

The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 2020131224

Methods for Synthesis of Radionuclide Complex

ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT] · Granted Thu Apr 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

DE 202020000818

Mittel zur äußeren Pflege der Haut von Tieren, insbesondere von Pferden

CP PHARMA HANDELSGESELLSCHAFT MBH [DE] · Granted Mon May 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Sun Apr 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640487

Solid state forms of Nilotinib salts

Teva Pharmaceuticals USA, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639278

Delivery of agents using metastable liposomes

LIPELLA PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639277

Multi-functional echogenic immunoliposomes for directed stem cell delivery to atheroma

The Board of Regents of the University of Texas System · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639289

Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction

CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639302

Use of CDK9 inhibitors to reduce cartilage degradation

The Regents of the University of California · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639272

Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device

Rani Therapeutics, LLC · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639375

Progesterone formulations

Compass Therapeutics LLC · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639320

Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis

KOREA UNITED PHARM. INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639383

Methods and compositions for engineering immunity

Sangamo Therapeutics, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639308

sGC stimulators

Cyclerion Therapeutics, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639357

Enzymes and methods for cleaving N-glycans from glycoproteins

The Regents of the University of California · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640771

Compositions and methods for treating and preventing macular degeneration

THE UNITED STATES OF AMERICA AS REPRESENTED BY THE · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640571

Human monoclonal antibodies specific for glypican-3 and use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640485

Methods and compounds for restoring mutant p53 function

PMV PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639360

Methods for treating hypophosphatemic disorders

Ultragenyx Pharmaceutical Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639348

Peptides with anti-cancer activity

IDP DISCOVERY PHARMA, S.L. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640770

Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640534

Therapeutically active compositions and their methods of use

Agios Pharmaceuticals, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640511

Hepatitis B antiviral agents

Enanta Pharmaceuticals, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639350

Methods and pharmaceutical compositions for improving wound healing using CD24

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640535

Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

The Board of Regents of the University of Oklahoma · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640558

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640570

Chimeric antigen receptors, compositions, and methods

Regents of the University of Minnesota · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640566

Nucleic acid molecules encoding antibodies to the human glucagon receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640791

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

The Regents of the University of California · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640517

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

Aurigene Discovery Technologies Limited · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640501

Methods of preparing inhibitors of influenza viruses replication

Vertex Pharmaceuticals Incorporated · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10640493

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

The Regents of the University of California · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639330

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Iovance Biotherapeutics, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10639303

Alkaloids and their preparation and application as anti-HSV-1 agents

OCEAN UNIVERSITY OF CHINA · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

AR 113437

INHIBIDORES MITOCONDRIALES PARA EL TRATAMIENTO DE TRASTORNOS DE PROLIFERACIÓN

BASILEA PHARM INT AG [CH] · Granted Wed May 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue May 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3118090

COMPOSITIONS ET PROCEDES POUR EDITION DU GENOME A MEDIATION PAR NHEJ

CRISPR THERAPEUTICS AG [CH] · Granted Thu May 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646443

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10647697

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646480

Formulations of pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646481

Pharmaceutical composition and administrations thereof

Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646435

Pasty bio-adhesive sustained release compositions

CARE & PHARMA PERSPECTIVES SA · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646474

Glucocorticoid receptor modulators to treat pancreatic cancer

Corcept Therapeutics Incorporated · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10647710

Thiazole derivative and applications thereof

Medshine Discovery Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10647711

Azepin-2-one derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646577

mTORC1 inhibitors

The Regents of the University of California · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646537

Traditional Chinese medicine for treating abdominal obesity

INFINITUS (CHINA) COMPANY LTD. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646475

SHMT inhibitors

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646438

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

The Board of Regents of the University of Texas System · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10646485

Process of making stable abuse-deterrent oral formulations

Collegium Pharmaceutical, Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)